The global drug screening market is projected to grow from $8.92 billion in 2024 to $10.36 billion in 2025 and $21.29 billion by 2030, representing a 15.5% compound annual growth rate from 2025 to 2030, MarketsandMarkets said. Growth is being supported by the rising prevalence of substance abuse, expanding workplace testing programs, increased monitoring of opioids and polysubstance use, and adoption of rapid point-of-care screening and liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmation. North America was the largest regional market in 2024, with about 48% of global revenue, while services were the largest offering segment and drug testing laboratories the largest end-user segment. Oral fluid samples are expected to be the fastest-growing sample type, at a 17.1% CAGR, and cannabis the fastest-growing drug type. Labcorp, Quest Diagnostics Incorporated, Abbott, OraSure Technologies, Thermo Fisher Scientific, F. Hoffmann-La Roche and Drägerwerk are among the leading companies.